{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:18Z","timestamp":1790398758699,"version":"4.1.0"},"reference-count":104,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5582\/bst.2026.01237","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:11:57Z","timestamp":1790028717000},"source":"Crossref","is-referenced-by-count":0,"title":["The spatiotemporal ecosystem of gallbladder cancer: From inflamed areas to invasive margins \u2015 Integrating biomechanical injury, the bile microenvironment, precursor lineages, and spatial niches"],"prefix":"10.5582","author":[{"given":"Qingyang","family":"Meng","sequence":"first","affiliation":[{"name":"Department of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China."},{"name":"Biliary Tract Disease Center of Zhongshan Hospital, Fudan University, Shanghai, China."},{"name":"Biliary Tract Disease Institute, Fudan University, Shanghai, China."},{"name":"Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China."},{"name":"Shanghai Engineering Research Center of Biliary Tract Minimal Invasive Surgery and Materials, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houbao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biliary Surgery, Zhongshan Hospital, Fudan University, Shanghai, China."},{"name":"Biliary Tract Disease Center of Zhongshan Hospital, Fudan University, Shanghai, China."},{"name":"Biliary Tract Disease Institute, Fudan University, Shanghai, China."},{"name":"Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China."},{"name":"Shanghai Engineering Research Center of Biliary Tract Minimal Invasive Surgery and Materials, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Roa JC, Garc\u00eda P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022; 8:69.","DOI":"10.1038\/s41572-022-00398-y"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wistuba II, Gazdar AF. Gallbladder cancer: Lessons from a rare tumour. Nat Rev Cancer. 2004; 4:695-706.","DOI":"10.1038\/nrc1429"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: Geographical distribution and risk factors. Int J Cancer. 2006; 118:1591-1602.","DOI":"10.1002\/ijc.21683"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Miranda-Filho A, Pi\u00f1eros M, Ferreccio C, Adsay V, Soerjomataram I, Bray F, Koshiol J. Gallbladder and extrahepatic bile duct cancers in the Americas: Incidence and mortality patterns and trends. Int J Cancer. 2020; 147:978-989.","DOI":"10.1002\/ijc.32863"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Piovani D, Nikolopoulos GK, Aghemo A, Lleo A, Alqahtani SA, Hassan C, Repici A, Bonovas S. Environmental risk factors for gallbladder cancer: Field-wide systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025; 23:1500-1513.","DOI":"10.1016\/j.cgh.2024.07.046"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wang X, Yu W, Jiang G, <i>et al<\/i>. Global epidemiology of gallstones in the 21st century: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2024; 22:1586-1595.","DOI":"10.1016\/j.cgh.2024.01.051"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003; 4:167-176.","DOI":"10.1016\/S1470-2045(03)01021-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Espinoza JA, Bizama C, Garc\u00eda P, Ferreccio C, Javle M, Miquel JF, Koshiol J, Roa JC. The inflammatory inception of gallbladder cancer. Biochim Biophys Acta. 2016; 1865:245-254.","DOI":"10.1016\/j.bbcan.2016.03.004"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jain K, Mohapatra T, Das P, Misra MC, Gupta SD, Ghosh M, Kabra M, Bansal VK, Kumar S, Sreenivas V, Garg PK. Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer. Ann Surg. 2014; 260:1073-1080.","DOI":"10.1097\/SLA.0000000000000495"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Huang D, Joo H, Song N, Cho S, Kim W, Shin A. Association between gallstones and the risk of biliary tract cancer: A systematic review and meta-analysis. Epidemiol Health. 2021; 43:e2021011.","DOI":"10.4178\/epih.e2021011"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: A meta-analysis. Br J Cancer. 2007; 96:1457-1461.","DOI":"10.1038\/sj.bjc.6603703"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tan W, Gao M, Liu N, Zhang G, Xu T, Cui W. Body mass index and risk of gallbladder cancer: Systematic review and meta-analysis of observational studies. Nutrients. 2015; 7:8321-8334.","DOI":"10.3390\/nu7105387"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gu J, Yan S, Wang B, Shen F, Cao H, Fan J, Wang Y. Type 2 diabetes mellitus and risk of gallbladder cancer: A systematic review and meta-analysis of observational studies. Diabetes Metab Res Rev. 2016; 32:63-72.","DOI":"10.1002\/dmrr.2671"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ding W, Chen Z, Ming Z, Chen Z, Yuan R, Jin J, Qian C, Ge Z. The effect of smoking on the risk of gallbladder cancer: A meta-analysis of observational studies. Eur J Gastroenterol Hepatol. 2013; 25:373-379.","DOI":"10.1097\/MEG.0b013e32835a870b"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Mhatre S, Wang Z, Nagrani R, Badwe R, Chiplunkar S, Mittal B, Yadav S, Zhang H, Chung CC, Patil P, Chanock S, Dikshit R, Chatterjee N, Rajaraman P. Common genetic variation and risk of gallbladder cancer in India: A case-control genome-wide association study. Lancet Oncol. 2017; 18:535-544.","DOI":"10.1016\/S1470-2045(17)30167-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hsing AW, Bai Y, Andreotti G, Rashid A, Deng J, Chen J, Goldstein AM, Han TQ, Shen MC, Fraumeni JF Jr, Gao YT. Family history of gallstones and the risk of biliary tract cancer and gallstones: A population-based study in Shanghai, China. Int J Cancer. 2007; 121:832-838.","DOI":"10.1002\/ijc.22756"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Morine Y, Shimada M, Takamatsu H, Araida T, Endo I, Kubota M, Toki A, Noda T, Matsumura T, Miyakawa S, Ishibashi H, Kamisawa T, Shimada H. Clinical features of pancreaticobiliary maljunction: Update analysis of 2nd Japan-nationwide survey. J Hepatobiliary Pancreat Sci. 2013; 20:472-480.","DOI":"10.1007\/s00534-013-0606-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kamisawa T, Kaneko K, Itoi T, Ando H. Pancreaticobiliary maljunction and congenital biliary dilatation. Lancet Gastroenterol Hepatol. 2017; 2:610-618.","DOI":"10.1016\/S2468-1253(17)30002-X"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Muraki T, Memis B, Reid MD, <i>et al<\/i>. Reflux-associated cholecystopathy: Analysis of 76 gallbladders from patients with supra-Oddi union of the pancreatic duct and common bile duct (pancreatobiliary maljunction) elucidates a specific diagnostic pattern of mucosal hyperplasia as a prelude to carcinoma. Am J Surg Pathol. 2017; 41:1167-1177.","DOI":"10.1097\/PAS.0000000000000882"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Muraki T, Pehlivanoglu B, Memis B, <i>et al<\/i>. Pancreatobiliary maljunction-associated gallbladder cancer is as common in the west, shows distinct clinicopathologic characteristics and offers an invaluable model for anatomy-induced reflux-associated physio-chemical carcinogenesis. Ann Surg. 2022; 276:e32-e39.","DOI":"10.1097\/SLA.0000000000004482"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Koshiol J, Wozniak A, Cook P, Adaniel C, Acevedo J, Az\u00f3car L, Hsing AW, Roa JC, Pasetti MF, Miquel JF, Levine MM, Ferreccio C, Gallbladder Cancer Chile Working Group. Salmonella enterica serovar Typhi and gallbladder cancer: A case-control study and meta-analysis. Cancer Med. 2016; 5:3310-3325.","DOI":"10.1002\/cam4.915"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Nagaraja V, Eslick GD. Systematic review with meta-analysis: The relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther. 2014; 39:745-750.","DOI":"10.1111\/apt.12655"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Iyer P, Barreto SG, Sahoo B, Chandrani P, Ramadwar MR, Shrikhande SV, Dutt A. Non-typhoidal Salmonella DNA traces in gallbladder cancer. Infect Agent Cancer. 2016; 11:12.","DOI":"10.1186\/s13027-016-0057-x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Scanu T, Spaapen RM, Bakker JM, <i>et al<\/i>. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe. 2015; 17:763-774.","DOI":"10.1016\/j.chom.2015.05.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pragasam AK, Maurya S, Jain K, <i>et al<\/i>. Invasive Salmonella Typhimurium colonizes gallbladder and contributes to gallbladder carcinogenesis through activation of host epigenetic modulator KDM6B. Cancer Lett. 2025; 618:217621.","DOI":"10.1016\/j.canlet.2025.217621"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. de Martel C, Plummer M, Parsonnet J, van Doorn LJ, Franceschi S. Helicobacter species in cancers of the gallbladder and extrahepatic biliary tract. Br J Cancer. 2009; 100:194-199.","DOI":"10.1038\/sj.bjc.6604780"},{"key":"27","unstructured":"27. Tsuchiya Y, Loza E, Villa-Gomez G, Trujillo CC, Baez S, Asai T, Ikoma T, Endoh K, Nakamura K. Metagenomics of microbial communities in gallbladder bile from patients with gallbladder cancer or cholelithiasis. Asian Pac J Cancer Prev. 2018; 19:961-967."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Song X, Wang X, Hu Y, <i>et al<\/i>. A metagenomic study of biliary microbiome change along the cholecystitis-carcinoma sequence. Clin Transl Med. 2020; 10:e97.","DOI":"10.1002\/ctm2.97"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Choi SJ, Kim Y, Jeon J, <i>et al<\/i>. Association of microbial dysbiosis with gallbladder diseases identified by bile microbiome profiling. J Korean Med Sci. 2021; 36:e189.","DOI":"10.3346\/jkms.2021.36.e189"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kirishima M, Yokoyama S, Matsuo K, <i>et al<\/i>. Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis. BMC Microbiol. 2022; 22:147.","DOI":"10.1186\/s12866-022-02557-3"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Liu S, Li W, Chen J, Li M, Geng Y, Liu Y, Wu W. The footprint of gut microbiota in gallbladder cancer: A mechanistic review. Front Cell Infect Microbiol. 2024; 14:1374238.","DOI":"10.3389\/fcimb.2024.1374238"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Salter SJ, Cox MJ, Turek EM, Calus ST, Cookson WO, Moffatt MF, Turner P, Parkhill J, Loman NJ, Walker AW. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 2014; 12:87.","DOI":"10.1186\/s12915-014-0087-z"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Eisenhofer R, Minich JJ, Marotz C, Cooper A, Knight R, Weyrich LS. Contamination in low microbial biomass microbiome studies: Issues and recommendations. Trends Microbiol. 2019; 27:105-117.","DOI":"10.1016\/j.tim.2018.11.003"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Hegyi P, Mal\u00e9th J, Walters JR, Hofmann AF, Keely SJ. Guts and gall: Bile acids in regulation of intestinal epithelial function in health and disease. Physiol Rev. 2018; 98:1983-2023.","DOI":"10.1152\/physrev.00054.2017"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Sharma N, Yadav M, Tripathi G, Mathew B, Bindal V, Falari S, Pamecha V, Maras JS. Bile multi-omics analysis classifies lipid species and microbial peptides predictive of carcinoma of gallbladder. Hepatology. 2022; 76:920-935.","DOI":"10.1002\/hep.32496"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Shukla VK, Shukla PK, Pandey M, Rao BR, Roy SK. Lipid peroxidation product in bile from patients with carcinoma of the gallbladder: A preliminary study. J Surg Oncol. 1994; 56:258-262.","DOI":"10.1002\/jso.2930560415"},{"key":"37","unstructured":"37. WHO Classification of Tumours Editorial Board. Digestive System Tumours. 5th ed. International Agency for Research on Cancer, Lyon, France, 2019."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Roa JC, Basturk O, Adsay V. Dysplasia and carcinoma of the gallbladder: Pathological evaluation, sampling, differential diagnosis and clinical implications. Histopathology. 2021; 79:2-19.","DOI":"10.1111\/his.14360"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Fukumura Y, Rong L, Maimaitiaili Y, Fujisawa T, Isayama H, Nakahodo J, Kikuyama M, Yao T. Precursor lesions of gallbladder carcinoma: Disease concept, pathology, and genetics. Diagnostics (Basel). 2022; 12:341.","DOI":"10.3390\/diagnostics12020341"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Nakanuma Y, Kakuda Y, Sugino T, Sato Y, Fukumura Y. Pathologies of precursor lesions of biliary tract carcinoma. Cancers (Basel). 2022; 14:5358.","DOI":"10.3390\/cancers14215358"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Duarte I, Llanos O, Domke H, Harz C, Valdivieso V. Metaplasia and precursor lesions of gallbladder carcinoma. Frequency, distribution, and probability of detection in routine histologic samples. Cancer. 1993; 72:1878-1884.","DOI":"10.1002\/1097-0142(19930915)72:6<1878::AID-CNCR2820720615>3.0.CO;2-2"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Roa I, Araya JC, Villaseca M, De Aretxabala X, Riedemann P, Endoh K, Roa J. Preneoplastic lesions and gallbladder cancer: An estimate of the period required for progression. Gastroenterology. 1996; 111:232-236.","DOI":"10.1053\/gast.1996.v111.pm8698204"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Sasatomi E, Tokunaga O, Miyazaki K. Precancerous conditions of gallbladder carcinoma: Overview of histopathologic characteristics and molecular genetic findings. J Hepatobiliary Pancreat Surg. 2000; 7:556-567.","DOI":"10.1007\/s005340070004"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Koshiol J, Bellolio E, Vivallo C, <i>et al<\/i>. Distribution of dysplasia and cancer in the gallbladder: An analysis from a high cancer-risk population. Hum Pathol. 2018; 82:87-94.","DOI":"10.1016\/j.humpath.2018.07.015"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Adsay V, Jang KT, Roa JC, Dursun N, Ohike N, Bagci P, Basturk O, Bandyopadhyay S, Cheng JD, Sarmiento JM, Escalona OT, Goodman M, Kong SY, Terry P. Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are \u22651.0 cm): Clinicopathologic and immunohistochemical analysis of 123 cases. Am J Surg Pathol. 2012; 36:1279-1301.","DOI":"10.1097\/PAS.0b013e318262787c"},{"key":"46","unstructured":"46. Yanagisawa N, Mikami T, Saegusa M, Okayasu I. More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages. Cancer Res. 2001; 61:19-22."},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Cheng Z, Jia Z, Li X, Chen L, Cai Y. Unmasking the silent killer: The hidden aggressiveness of signet-ring cell carcinoma in gallbladder cancer. Biosci Trends. 2024; 18:379-387.","DOI":"10.5582\/bst.2024.01230"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Ajiki T, Fujimori T, Onoyama H, Yamamoto M, Kitazawa S, Maeda S, Saitoh Y. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut. 1996; 38:426-429.","DOI":"10.1136\/gut.38.3.426"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Roa JC, Roa I, Correa P, Vo Q, Araya JC, Villaseca M, Guzm\u00e1n P, Schneider BG. Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol. 2005; 40:79-86.","DOI":"10.1007\/s00535-004-1497-4"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Priya TP, Kapoor VK, Krishnani N, Agrawal V, Agrawal S. Role of E-cadherin gene in gall bladder cancer and its precursor lesions. Virchows Arch. 2010; 456:507-514.","DOI":"10.1007\/s00428-010-0908-6"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Lin J, Peng X, Dong K, Long J, Guo X, Li H, Bai Y, Yang X, Wang D, Lu X, Mao Y, Sang X, Ji X, Zhao H, Liang H. Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer. Nat Commun. 2021; 12:4753.","DOI":"10.1038\/s41467-021-25012-9"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Pirenne S, Manzano-N\u00fa\u00f1ez F, Loriot A, Cordi S, Desmet L, Aydin S, Hubert C, Toffoli S, Limaye N, Sempoux C, Komuta M, Gatto L, Lemaigre FP. Spatial transcriptomics profiling of gallbladder adenocarcinoma: A detailed two-case study of progression from precursor lesions to cancer. BMC Cancer. 2024; 24:1025.","DOI":"10.1186\/s12885-024-12770-0"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Chung T, Oh S, Won J, Park J, Yoo JE, Hwang HK, Choi GH, Kang CM, Han DH, Kim S, Park YN. Genomic and transcriptomic signatures of sequential carcinogenesis from papillary neoplasm to biliary tract cancer. J Hepatol. 2025; 83:119-130.","DOI":"10.1016\/j.jhep.2025.01.007"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Nagao M, Fukuda A, Omatsu M, <i>et al<\/i>. Concurrent activation of Kras and canonical Wnt signaling induces premalignant lesions that progress to extrahepatic biliary cancer in Mice. Cancer Res. 2022; 82:1803-1817.","DOI":"10.1158\/0008-5472.CAN-21-2176"},{"key":"55","doi-asserted-by":"publisher","unstructured":"55. Min Q, Jiang X, Cheng Y, Yu X, Yang T, Gu G, Mei K, Shao M. CLDN18 identifies high-risk precursor lesions in gallbladder carcinogenesis: A study of the TFF2-positive pseudopyloric metaplasia to intestinal metaplasia axis. Virchows Arch. 2026. doi: 10.1007\/s00428-026-04592-1.","DOI":"10.1007\/s00428-026-04592-1"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Xia Y, Zhang X, Liu Y, Sheng J, Hu S, Li J, Yuan L, Zhu S, Li H, Wu X, Fan J. Single-cell transcriptomics uncovers malignant potential of gallbladder adenomyomatosis and identifies PRDX1+ immunosuppressive macrophages in gallbladder carcinoma. Int J Surg. 2026; 112:11342-11364.","DOI":"10.1097\/JS9.0000000000004916"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Li M, Zhang Z, Li X, <i>et al<\/i>. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014; 46:872-876.","DOI":"10.1038\/ng.3030"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Li M, Liu F, Zhang F, <i>et al<\/i>. Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis. Gut. 2019; 68:1024-1033.","DOI":"10.1136\/gutjnl-2018-316039"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Nepal C, Zhu B, O&apos;Rourke CJ, <i>et al<\/i>. Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. J Hepatol. 2021; 74:1132-1144.","DOI":"10.1016\/j.jhep.2020.11.033"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Giraldo NA, Drill E, Satravada BA, <i>et al<\/i>. Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention. Clin Cancer Res. 2022; 28:5359-5367.","DOI":"10.1158\/1078-0432.CCR-22-1954"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Yadav S, DE Sarkar N, Kumari N, Krishnani N, Kumar A, Mittal B. Targeted gene sequencing of gallbladder carcinoma identifies high-impact somatic and rare germline mutations. Cancer Genomics Proteomics. 2017; 14:495-506.","DOI":"10.21873\/cgp.20059"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Goldin RD, Roa JC. Gallbladder cancer: A morphological and molecular update. Histopathology. 2009; 55:218-229.","DOI":"10.1111\/j.1365-2559.2008.03192.x"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Br\u00e4gelmann J, Barahona Ponce C, Marcelain K, <i>et al<\/i>. Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer. Hepatology. 2021; 73:2293-2310.","DOI":"10.1002\/hep.31585"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Hu YP, Jin YP, Wu XS, <i>et al<\/i>. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p\/SET\/AKT axis. Mol Cancer. 2019; 18:167.","DOI":"10.1186\/s12943-019-1097-9"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Wang Y, Li S, Bo X, Li Y, Wang C, Nan L, Zhang D, Liu H, Zhang J. CircRNome-wide characterisation reveals the promoting role of circAATF in anti-PD-L1 immunotherapy of gallbladder carcinoma. Clin Transl Med. 2024; 14:e70060.","DOI":"10.1002\/ctm2.70060"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Cheng H, Sun Y, Yu X, Zhou D, Ding J, Wang S, Ma F. FASN promotes gallbladder cancer progression and reduces cancer cell sensitivity to gemcitabine through PI3K\/AKT signaling. Drug Discov Ther. 2023; 17:328-339.","DOI":"10.5582\/ddt.2023.01036"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Sun Y, Li X, Cheng H, Wang S, Zhou D, Ding J, Ma F. Drug resistance and new therapies in gallbladder cancer. Drug Discov Ther. 2023; 17:220-229.","DOI":"10.5582\/ddt.2023.01013"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Wang X, Liu C, Chen J, <i>et al<\/i>. Single-cell dissection of remodeled inflammatory ecosystem in primary and metastatic gallbladder carcinoma. Cell Discov. 2022; 8:101.","DOI":"10.1038\/s41421-022-00445-8"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Cheng H, Zhou D, Wang S, Ding J, Ma F. The immunological characteristics of gallbladder carcinoma and advances in immunotherapy practices. Biosci Trends. 2021; 15:9-15.","DOI":"10.5582\/bst.2020.01039"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Zhang Y, Zuo C, Liu L, <i>et al<\/i>. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer. J Hepatol. 2021; 75:1128-1141.","DOI":"10.1016\/j.jhep.2021.06.023"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Chen P, Wang Y, Li J, Bo X, Wang J, Nan L, Wang C, Ba Q, Liu H, Wang H. Diversity and intratumoral heterogeneity in human gallbladder cancer progression revealed by single-cell RNA sequencing. Clin Transl Med. 2021; 11:e462.","DOI":"10.1002\/ctm2.462"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Wang J, Ren M, Yu J, Hu M, Wang X, Ma W, Jiang X, Cui J. Single-cell RNA sequencing highlights the functional role of human endogenous retroviruses in gallbladder cancer. EBioMedicine. 2022; 85:104319.","DOI":"10.1016\/j.ebiom.2022.104319"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. He H, Chen S, Yu Y, <i>et al<\/i>. Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer. Gut. 2024; 73:1529-1542.","DOI":"10.1136\/gutjnl-2023-331773"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Zhang Y, Zuo C, Li Y, Liu L, Yang B, Xia J, Cui J, Xu K, Wu X, Gong W, Liu Y. Single-cell characterization of infiltrating T cells identifies novel targets for gallbladder cancer immunotherapy. Cancer Lett. 2024; 586:216675.","DOI":"10.1016\/j.canlet.2024.216675"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. He Z, Cao J, Wang X, Yang S, Gao H, Yu Y, Di Z, Peng C. Single-cell analyses unravel ecosystem dynamics and intercellular crosstalk during gallbladder cancer malignant transformation. Hepatol Commun. 2025; 9:e0697.","DOI":"10.1097\/HC9.0000000000000697"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Nie J, Zhang S, Guo Y, <i>et al<\/i>. Mapping of the T-cell landscape of biliary tract cancer unravels anatomic subtype-specific heterogeneity. Cancer Res. 2025; 85:704-722.","DOI":"10.1158\/0008-5472.CAN-24-1173"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Terasaki F, Kumagai S, Fukuda A, Tanaka Y, Irie T, Ito S, Yamada M, Onoe S, Mizuno T, Kokuryo T, Koyama S, Karube K, Nishikawa H, Ebata T. KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer. Int Immunol. 2026; 38:236-250.","DOI":"10.1093\/intimm\/dxaf065"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Zhou T, Wu Y, Li S, <i>et al<\/i>. Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression. Nat Genet. 2025; 57:1935-1949.","DOI":"10.1038\/s41588-025-02236-9"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Charbel A, Tavernar L, Albrecht T, Brinkmann F, Verheij J, Roos E, Vogel MN, K\u00f6hler B, Springfeld C, Brobeil A, Schirmacher P, Singer S, Mehrabi A, Roessler S, Goeppert B. Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis. Br J Cancer. 2022; 127:1603-1614.","DOI":"10.1038\/s41416-022-01933-0"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Oguro S, Ino Y, Shimada K, Hatanaka Y, Matsuno Y, Esaki M, Nara S, Kishi Y, Kosuge T, Hiraoka N. Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer. Cancer Sci. 2015; 106:1750-1760.","DOI":"10.1111\/cas.12825"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Lin J, Long J, Wan X, Chen J, Bai Y, Wang A, Yang X, Wu Y, Robson SC, Sang X, Zhao H. Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. BMC Cancer. 2018; 18:766.","DOI":"10.1186\/s12885-018-4651-8"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Patil PA, Lombardo K, Cao W. Immune microenvironment in gallbladder adenocarcinomas. Appl Immunohistochem Mol Morphol. 2021; 29:557-563.","DOI":"10.1097\/PAI.0000000000000922"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. He X, Peng Y, He G, Ye H, Liu L, Zhou Q, Shi J, Fu S, Wang J, Zhou Z, Li W. Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer. J Transl Med. 2023; 21:717.","DOI":"10.1186\/s12967-023-04589-3"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Li Y, Yang B, Miao H, Liu L, Wang Z, Jiang C, Yang Y, Qiu S, Li X, Geng Y, Zhang Y, Liu Y. Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma. Hepatology. 2023; 78:1352-1367.","DOI":"10.1097\/HEP.0000000000000028"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Rao D, Li J, Zhang M, <i>et al<\/i>. Multi-model analysis of gallbladder cancer reveals the role of OxLDL-absorbing neutrophils in promoting liver invasion. Exp Hematol Oncol. 2024; 13:58.","DOI":"10.1186\/s40164-024-00521-7"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Hou M, Chen J, Jiang Y, Liu C, Wang X, Liu E, Zong Y, Gu M, Meng Z, Wang S, Wei W, Liu Q, Wang H, Fu J, Zhao X. Single-cell analysis reveals CD34+CD90+ endothelial cells promote tumor metastasis in gallbladder cancer. NPJ Precis Oncol. 2025; 9:242.","DOI":"10.1038\/s41698-025-01040-2"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Li M, Liu Z, Shan S, <i>et al<\/i>. Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progression. J Clin Invest. 2026; 136:e193672.","DOI":"10.1172\/JCI193672"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Wan X, Xiao J, Tam SST, Cai M, Sugimura R, Wang Y, Wan X, Lin Z, Wu AR, Yang C. Integrating spatial and single-cell transcriptomics data using deep generative models with SpatialScope. Nat Commun. 2023; 14:7848.","DOI":"10.1038\/s41467-023-43629-w"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Wang T, Roach MJ, Harvey K, <i>et al<\/i>. snPATHO-seq, a versatile FFPE single-nucleus RNA sequencing method to unlock pathology archives. Commun Biol. 2024; 7:1340.","DOI":"10.1038\/s42003-024-07043-2"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Wang H, Huang R, Nelson J, Gao C, Tran M, Yeaton A, Krishna S, Felt K, Pfaff KL, Bowman T, Rodig SJ, Wei K, Goods BA, Farhi SL. Systematic benchmarking of imaging spatial transcriptomics platforms in FFPE tissues. Nat Commun. 2025; 16:10215.","DOI":"10.1038\/s41467-025-64990-y"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Cheng Z, Yang C, Zhao Q, Zhong J, Zhang J, Jin R, Li Y, Ta N, Wu D, Yuan Z, Sun W, Wang R. Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer. Cancer Sci. 2024; 115:1979-1988.","DOI":"10.1111\/cas.16142"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Tang QY, Zhang YJ, Wu ZY, <i>et al<\/i>. Single-cell profiling unveils the immuno-favorable tumor microenvironment remodeling after successful neoadjuvant therapy for advanced gallbladder cancer. Int J Surg. 2026; 112:4110-4124.","DOI":"10.1097\/JS9.0000000000003883"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Xuan Z, Hu H, Xu J, Ling X, Zhang L, Li W, Li J, Zhu C, Song Y, Zhang X, Rao J, Wang Y, Cheng F. Adrenomedullin inhibits the efficacy of combined immunotherapy and targeted therapy in biliary tract cancer by disrupting endothelial cell functions. J Cell Mol Med. 2025; 29:e70460.","DOI":"10.1111\/jcmm.70460"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. He X, Yang X, Xu S, He X, He G, Ye H, Zhou Q, Ren J, Liu L, Wang J, Peng Y, Zhou Z, Li W. Spatial profiling defines three immunophenotypes and a perineural invasion-associated immune-evasion niche in gallbladder cancer. JHEP Rep. 2026; 8:101807.","DOI":"10.1016\/j.jhepr.2026.101807"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Zhao J, Zhu J, Yang Z, <i>et al<\/i>. Extracellular vesicle-mediated O-GlcNAcase transfer drives neuronal necroptosis to facilitate gallbladder cancer perineural invasion. Cancer Res. 2026; 86:1392-1413.","DOI":"10.1158\/0008-5472.CAN-25-2237"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Fang L, Qiu Z, Xu L, Hu F, Tao Y, Ding S, Zhou J, Wang L, Chen L. Comparative study of contrast-enhanced ultrasound and contrast-enhanced computed tomography in the diagnosis of benign and malignant lesions of the gallbladder. Drug Discov Ther. 2026; 19:414-424.","DOI":"10.5582\/ddt.2025.01105"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Zeng D, Wang Y, Wen N, Lu J, Li B, Cheng N. Incidental gallbladder cancer detected during laparoscopic cholecystectomy: Conversion to extensive resection is a feasible choice. Front Surg. 2024; 11:1418314.","DOI":"10.3389\/fsurg.2024.1418314"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362:1273-1281.","DOI":"10.1056\/NEJMoa0908721"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Oh DY, Ruth He A, Qin S, <i>et al<\/i>. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022; 1:EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Kelley RK, Ueno M, Yoo C, <i>et al<\/i>. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401:1853-1865.","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Oh DY, He AR, Bouattour M, <i>et al<\/i>. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024; 9:694-704.","DOI":"10.1016\/S2468-1253(24)00095-5"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Xu R, Zhou J, Yang J, Yu Y, Wang H, Zhang Z, Yang J, Zhang G, Liao R. First-line systemic therapy and sequencing options in advanced biliary tract cancer: A systematic review and network meta-analysis. Biosci Trends. 2025; 18:555-562.","DOI":"10.5582\/bst.2024.01376"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Kim R, Park JK, Kwon M, An M, Hong JY, Park JO, Lim SH, Kim ST. Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: A phase II trial of pembrolizumab. Oncol Res. 2025; 33:57-65.","DOI":"10.32604\/or.2024.049054"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Cheng H, Zhou D, Wang S, Ding J, Ma F. Orphan drugs in different countries and development of new drugs to treat biliary tract cancer. Intractable Rare Dis Res. 2021; 10:146-147.","DOI":"10.5582\/irdr.2021.01038"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/advpub\/0\/advpub_2026.01237\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:20:15Z","timestamp":1790396415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/advpub\/0\/advpub_2026.01237\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":104,"URL":"https:\/\/doi.org\/10.5582\/bst.2026.01237","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026.01237"}}